Status:
UNKNOWN
Autotaxin (ATX) as a Marker for Breast Cancer
Lead Sponsor:
Assiut University
Conditions:
Breast Cancer
Eligibility:
FEMALE
19-69 years
Phase:
NA
Brief Summary
Breast cancer is the leading cause of cancer death in women worldwide. According to the GLOBOCAN 2018 worldwide estimates of cancer incidence and mortality, in 2018, about 2,088,849 new cases were dia...
Detailed Description
Breast cancer is the most common malignancy in females in Egypt. It accounts for 32 % of cancer in women . Breast cancer in Egypt carries an unfavorable prognosis with 29% mortality and 3.7:1 incidenc...
Eligibility Criteria
Inclusion
- The study will be conducted on one hundred female individuals; 80 newly diagnosed breast cancer patients before any treatment or surgical intervention and 20 apparently normal female individuals.
Exclusion
- Patients with any other type of malignant or benign tumors, renal failure, cardiovascular diseases and liver cirrhosis were excluded from our study.
- Past history of chemotherapy or surgical treatment of any malignancy.
- Inflammatory diseases (e.g.bronchitis) or autoimmune diseases (e.g.rheumatoid arthritis).
Key Trial Info
Start Date :
May 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04328194
Start Date
May 1 2021
End Date
November 1 2022
Last Update
March 31 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.